Abstract
To assess potential health risks of nanoparticles by means of in vitro or in vivo assays and to determine dose-action curves a defined and reproducible method of particle administration is required. The interpretation of the toxicological results should be based on a comprehensive chemical-physical characterization of the particles used. Therefore, we developed a method to suspend nanoparticles stably and homogenously in physiological media. Our approach consist of three steps: (1) physical-chemical characterisation of the powders as delivered, (2) preparation and characterization of a non-physiological electro-statically stabilized nanoparticle suspension and (3) assessment of the nanoparticles behaviour in physiological media with or without proteins. This approach is demonstrated on a titanium dioxide and a tungsten carbide nanopowder. Results showed that particles agglomerate in protein-free medium within minutes, whereas in the presence of bovine serum albumin or foetal bovine serum an agglomeration is hindered.